Swindon & Wiltshire Business News

Print

Work starts on $27 million pharmaceutical facility

on .

Peter Allen, general manager, Catalent Swindon; Kris Talikowski, Switch on to Swindon; Chris Parson, Swindon Borough Council; Jonathan Arnold, Catalent; Thomas Yezza, Catalent; Mario Gargiulo, Catalent; Simon Wright- Catalent; Steven Thane, DIT; Ian Larrard Business West; Paddy Bradley, Swindon & Wiltshire Local Enterprise PartnershipPeter Allen, general manager, Catalent Swindon; Kris Talikowski, Switch on to Swindon; Chris Parson, Swindon Borough Council; Jonathan Arnold, Catalent; Thomas Yezza, Catalent; Mario Gargiulo, Catalent; Simon Wright- Catalent; Steven Thane, DIT; Ian Larrard Business West; Paddy Bradley, Swindon & Wiltshire Local Enterprise PartnershipPharmaceutical development company Catalent has started work on a new $27 million facility in Swindon.

The opening of the new 40,000-square feet development and manufacturing site at Blagrove will create an extra 100 jobs.

Representatives from Switch on to Swindon, Swindon Borough Council, the Department of International Trade, Business West and Swindon & Wiltshire Local Enterprise Partnership, joined Catalent management on Wednesday, September 11 for a ground-breaking ceremony.

Catalent's current 250,000-square feet Swindon site is home to the company’s Zydis technology which allows for the manufacture of tablets that dissolve instantly in the mouth without water, and is used in many over-the-counter medicines for conditions such as allergies and diarrhoea.

The investment will see the site almost double its manufacturing capacity for tablets, as it introduces its new technology, Zydis Ultra, which increases the dose that can be incorporated within a tablet.

The facility currently employs over 650 people, and manufactures 1.2 billion individual doses of medicines for patients and consumers of over-the-counter medicines around the world each year.

Peter Allen, general manager of Catalent Swindon, said: “The medicines that we make here in Swindon help patients all around the world, and are commonplace in many peoples’ lives as a convenient way to take tablets.

“We are very proud of the scientific team that we have here that has developed a revolutionary technology which will allow us to expand and grow, and widen the number of potential life-changing conditions we can treat.”